Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 1200 iu; factor viii, quantity: 500 iu - injection, powder for - excipient ingredients: sucrose; trometamol; sodium chloride; albumin; sodium citrate dihydrate; calcium chloride dihydrate - von willebrand disease (vwd) - treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated. haemophilia a (congenital fviii deficiency) - prophylaxis and treatment of bleeding in patients with haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 1200 iu; factor viii, quantity: 500 iu - injection, powder for - excipient ingredients: sodium citrate dihydrate; trometamol; calcium chloride dihydrate; albumin; sucrose; sodium chloride - von willebrand disease (vwd) - treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated. haemophilia a (congenital fviii deficiency) - prophylaxis and treatment of bleeding in patients with haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - von willebrand factor, quantity: 600 iu; factor viii, quantity: 250 iu - injection, powder for - excipient ingredients: calcium chloride dihydrate; sodium chloride; trometamol; sucrose; albumin; sodium citrate dihydrate - von willebrand disease (vwd) - treatment of haemorrhage or prevention and treatment of surgical bleeding in patients with vwd, when desmopressin (ddavp) treatment alone is ineffective or contraindicated. haemophilia a (congenital fviii deficiency) - prophylaxis and treatment of bleeding in patients with haemophilia a.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 3.2 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine - evogam is indicated in adults and children for replacement therapy in: * primary immunodeficiency disease (pid) and * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 1.6 g - injection, solution - excipient ingredients: glycine; human immunoglobulin a - evogam is indicated in adults and children for replacement therapy in: * primary immunodeficiency disease (pid) and * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 0.8 g - injection, solution - excipient ingredients: glycine; human immunoglobulin a - evogam is indicated in adults and children for replacement therapy in: * primary immunodeficiency disease (pid) and * symptomatic hypogammaglobulinaemia secondary to underlying disease or treatment.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 20 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine - intragam 10 is indicated for replacement igg therapy in: - primary immunodeficiency disease (pid) - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. intragam 10 is indicated for immunomodulatory therapy in: - immune thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - kawasaki disease - guillain-barr? syndrome (gbs) - chronic inflammatory demyelinating polyneuropathy (cidp) - multifocal motor neuropathy (mmn) - myasthenia gravis (mg) in acute exacerbation (myasthenic crisis) or prior to surgery and/or thymectomy; as maintenance therapy for moderate to severe mg when other treatments have been ineffective or caused intolerable side effects - short-term therapy for severely affected nonparaneoplastic lambert-eaton myasthenic syndrome (lems) patients - treatment of significant functional impairment in patients who have a verified diagnosis of stiff person syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 10 g - injection, solution - excipient ingredients: glycine; human immunoglobulin a - intragam 10 is indicated for replacement igg therapy in: - primary immunodeficiency disease (pid) - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. intragam 10 is indicated for immunomodulatory therapy in: - immune thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - kawasaki disease - guillain-barr? syndrome (gbs) - chronic inflammatory demyelinating polyneuropathy (cidp) - multifocal motor neuropathy (mmn) - myasthenia gravis (mg) in acute exacerbation (myasthenic crisis) or prior to surgery and/or thymectomy; as maintenance therapy for moderate to severe mg when other treatments have been ineffective or caused intolerable side effects - short-term therapy for severely affected nonparaneoplastic lambert-eaton myasthenic syndrome (lems) patients - treatment of significant functional impairment in patients who have a verified diagnosis of stiff person syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 5 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine - intragam 10 is indicated for replacement igg therapy in: - primary immunodeficiency disease (pid) - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. intragam 10 is indicated for immunomodulatory therapy in: - immune thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - kawasaki disease - guillain-barr? syndrome (gbs) - chronic inflammatory demyelinating polyneuropathy (cidp) - multifocal motor neuropathy (mmn) - myasthenia gravis (mg) in acute exacerbation (myasthenic crisis) or prior to surgery and/or thymectomy; as maintenance therapy for moderate to severe mg when other treatments have been ineffective or caused intolerable side effects - short-term therapy for severely affected nonparaneoplastic lambert-eaton myasthenic syndrome (lems) patients - treatment of significant functional impairment in patients who have a verified diagnosis of stiff person syndrome.

Australia - English - Department of Health (Therapeutic Goods Administration)

csl behring australia pty ltd - human immunoglobulin g, quantity: 2.5 g - injection, solution - excipient ingredients: human immunoglobulin a; glycine - intragam 10 is indicated for replacement igg therapy in: - primary immunodeficiency disease (pid) - myeloma and chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections - congenital or acquired immune deficiency syndrome with recurrent infections. intragam 10 is indicated for immunomodulatory therapy in: - immune thrombocytopenic purpura (itp), in adults or children at high risk of bleeding or prior to surgery to correct the platelet count - allogeneic bone marrow transplantation - kawasaki disease - guillain-barr? syndrome (gbs) - chronic inflammatory demyelinating polyneuropathy (cidp) - multifocal motor neuropathy (mmn) - myasthenia gravis (mg) in acute exacerbation (myasthenic crisis) or prior to surgery and/or thymectomy; as maintenance therapy for moderate to severe mg when other treatments have been ineffective or caused intolerable side effects - short-term therapy for severely affected nonparaneoplastic lambert-eaton myasthenic syndrome (lems) patients - treatment of significant functional impairment in patients who have a verified diagnosis of stiff person syndrome.